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in the neutralization and blocking
ELISA assays, mostly because of
SLEV. Complete test results from
these horses, as well as from
Colombian cattle and chickens, will
be presented elsewhere.
These serologic data should be
considered indirect evidence of WNV
activity in Colombia. We encourage
Colombian human and animal health
authorities to enhance surveillance for
human, equine, and avian disease
attributable to WNV. Efforts are need-
ed to isolate the virus or detect specif-
ic viral RNA to confirm this finding
and to identify vectors and vertebrate
hosts involved in WNV transmission
in Colombia.
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Wild Poliovirus
Type 1, Central
African Republic 
To the Editor: In this article we
summarize the investigation and
response to the reemergence of wild
poliovirus (WPV) type 1 in the
Central African Republic (CAR) in
2003. Since 2000, reported annual
routine vaccination coverage with >3
doses of oral polio vaccine (OPV) has
been very low in CAR (<50%);
National Immunization Days have
been conducted every year since
1996, except in 2002 (1). 
From December 2003 to November
2004, the active acute flaccid paralysis
surveillance system reported 112 cases
of acute flaccid paralysis suspected to
be polio-myelitis and 4 deaths (case-
fatality ratio 4%). Fecal samples were
collected and sent to the Institut
Pasteur de Bangui. WPV type 1
(WPV1) was isolated in 30 cases
(27%), vaccine polioviruses in 15
cases (5 type 1, 5 type 2, and 6 type 3)
(13%), and nonpolio enteroviruses in
18 cases (16%). Epidemiologic inves-
tigations showed that 97% of patients
with poliomyelitis received <3 doses
of OPV and 93% of patients were <5
years of age. Isolates were sent to the
National Institute for Virology in
Johannesburg, South Africa, for
sequencing. All viruses were type 1
and could be traced to common ances-
tral strains that circulate in disease-
endemic reservoirs shared by northern
Nigeria and southern Niger (WEAF-B
genotype). The first importation
occurred in Chad in August 2003 from
northeastern Nigeria, and the outbreak
spread to the adjacent countries of
Cameroon in October 2003 and the
CAR in December 2003. 
In CAR, the first case occurred in a
19-month-old child living in Ndjoh
village north of Bossembélé in Ombela
M’Poko. A special mission by the
World Health Organization/ CAR offi-
cer determined that the child had not
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received OPV and had traveled 200
km into a northern region a few weeks
before the onset date of December 16,
2003. The last case of acute flaccid
paralysis in this region was noted on
November 23, 1999. Supplemental
immunization activities were conduct-
ed from March to April 2004.
However, collected funds were not
enough to cover the entire country, and
only sanitary regions 1, 3, 4, 5, and 7
were included. The OPV coverage rate
was estimated at 104% for the first
round and 141% for the second round
(CAR Ministry of Health, unpub.
data). The second case occurred in
April 2004 in Gadzi in sanitary region
2 in a 6-year-old nomad child who had
not received OPV. The third case
occurred in May 2004, in a village near
where the second case was diagnosed,
in a 23-month-old child who had not
received OPV. Twenty-five other cases
occurred between July and November
in sanitary region 2 (Figure). 
This outbreak is the largest epidem-
ic of WPV1 in CAR since July 2000,
when the last case of WPV1 was iso-
lated (2). Probable reestablishment of
endemic poliovirus and possible diffu-
sion of WPV1 to countries further
south, such as the Democratic
Republic of Congo, is a concern. Four
main reasons may explain this out-
break: 1) the close links with coun-
tries, such as Chad and Cameroon,
where WPV1 recently reemerged; 2)
declining rates of routine vaccination
and low population immunity after
disruption of health service infrastruc-
tures and road networks; 3) displaced
persons’ living in crowded areas with
little sanitation and poor water supply;
and 4) lack of response preparedness
to WPV importation. Epidemiologic
investigation of the first case was not
conducted until >1 month after onset
and implementation of the polio im-
munization initiative in a limited area.
In May 2004, a decision was made
by African Union health ministers to
conduct a series of synchronized
poliovirus campaigns across the
African continent. Four rounds of
National Immunization Days were
conducted in CAR from August to
December 2004. The OPV coverage
rate in 600,000 children <5 years of
age was estimated to be 89% in
August, 98% in September, 102% in
November, and 100% in December.
Since November 2004, only 1 WPV1
case has been virologically confirmed
in sanitary region 2. WPV1 has not
been isolated in 2005.
To restore the gains made in polio
eradication in Central Africa, WPV
transmission must be interrupted in
Nigeria and Niger (3). Until then,
neighboring countries must implement
high routine vaccination coverage
and high-quality, supplemental
immunization activities. In 2002,
these steps successfully prevented
importation of WPV into Bangladesh
and Nepal during a resurgence of
polio in India. Surveillance standards
must also be maintained to ensure the
rapid detection of any WPV importa-
tion, thus allowing timely response
and containment.
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Figure. Supplementary immunization activities (SIA) areas, military conflicts, and migra-
tion movements, Central African Republic, 2001–2004. Gray star indicates first case of
wild poliovirus type 1, Ombella-M’Poko (SR1), 2003; white stars indicate 2004 cases (1 in
Ouham [SR3], 3 in Nana-Mambere [SR2], 3 in Sangha-Mbaere [SR2], and 23 in
Mambere-Kadei [SR2]); circles indicate SIA areas, March–April 2004; arrows indicate
2001–2003 migration; dark gray shading indicates military conflict areas, 2001–2003.